RxDoctor Payments DataLook up a doctor →

Kerri Gray, MD

Family Medicine · Bethesda, MDNPI 1700880184

Payments from drug & device makers

$16,169in general payments, 2019–2025

Across 887 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • AbbVie$3K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Pfizer$842
  • Novo Nordisk$825
  • Lilly USA, LLC$657
  • plus $7K from 41 others

What the payments were for

  • Consulting fees$4663%
  • Food & beverage$15,48096%
  • Education$2231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,169 in reported general payments places this provider in the 95th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$267,618
Medicare patients
552
Services billed
3,397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol65$79,881
JardianceEmpagliflozin47$58,279
MounjaroTirzepatide44$53,403
OzempicSemaglutide46$45,842
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$31,385
EliquisApixaban19$27,726
MyrbetriqMirabegron11$11,406
VascepaIcosapent Ethyl11$5,120
Testosterone18$3,738
Rosuvastatin Calcium138$3,654
Atorvastatin Calcium228$3,156
SynthroidLevothyroxine Sodium43$3,153
PaxlovidNirmatrelvir/Ritonavir28$2,858
Nebivolol Hcl36$2,303
Lidocaine14$2,053

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$2,893$79,88165 claims
Boehringer IngelheimJardiance$29$58,27947 claims
Lilly USA, LLCMounjaro$657$53,40344 claims
Novo NordiskOzempic$825$45,84246 claims
GSKTrelegy Ellipta$602$31,38523 claims
PfizerEliquis, Paxlovid$842$30,58447 claims
Astellas Pharma US IncMyrbetriq$256$11,40611 claims
AbbVieSynthroid$2,789$3,15343 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$1,926166 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Bethesda

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →